

# Basic Annual Drug List Updates

October 2019

<b>TRADE NAME (generic name) or generic name</b>	<b>Brand/Generic</b>	<b>Description of Change</b>
INBRIJA (levodopa inhal powder cap 42 mg)	Brand	Addition, Preferred Status
KALYDECO (ivacaftor packet 25 mg)	Brand	Addition, Preferred Status
LOTEMAX SM (loteprednol etabonate ophth gel 0.38%)	Brand	Addition, Preferred Status
MAYZENT (siponimod fumarate tab 0.25 mg (base equiv))	Brand	Addition, Preferred Status
MAYZENT (siponimod fumarate tab 2 mg (base equiv))	Brand	Addition, Preferred Status
SKYRIZI (risankizumab-rzaa sol prefilled syringe 2 x 75 mg/0.83ml kit)	Brand	Addition, Preferred Status
SYMDEKO (tezacaftor-ivacaftor 50-75 mg & ivacaftor 75 mg tab tbpk)	Brand	Addition, Preferred Status
SYMJEPI (epinephrine soln prefilled syringe 0.15 mg/0.3ml (1:2000))	Brand	Addition, Preferred Status
SYMJEPI (epinephrine solution prefilled syringe 0.3 mg/0.3ml (1:1000))	Brand	Addition, Preferred Status
TREMFYA (guselkumab soln pen-injector 100 mg/ml)	Brand	Addition, Preferred Status
TREMFYA (guselkumab soln prefilled syringe 100 mg/ml)	Brand	Addition, Preferred Status

A division of Health Care Service Corporation, a Mutual Legal Reserve Company, an independent licensee of the Blue Cross Blue Shield Association. Blue Cross and Blue Shield of Texas (BCBSTX) contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. BCBSTX, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics LLC.